Cargando…

Elongation factor-2 kinase is a critical determinant of the fate and antitumor immunity of CD8(+) T cells

eEF-2K has important roles in stress responses and cellular metabolism. We report here a previously unappreciated but critical role of eEF-2K in regulating the fate and cytocidal activity of CD8(+) T cells. CD8(+) T cells from eEF-2K KO mice were more proliferative but had lower survival than their...

Descripción completa

Detalles Bibliográficos
Autores principales: Das, Jugal Kishore, Ren, Yijie, Kumar, Anil, Peng, Hao-Yun, Wang, Liqing, Xiong, Xiaofang, Alaniz, Robert C., de Figueiredo, Paul, Ren, Xingcong, Liu, Xiaoqi, Ryazonov, Alexey G., Yang, Jin-Ming, Song, Jianxun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809536/
https://www.ncbi.nlm.nih.gov/pubmed/35108044
http://dx.doi.org/10.1126/sciadv.abl9783
_version_ 1784644036873682944
author Das, Jugal Kishore
Ren, Yijie
Kumar, Anil
Peng, Hao-Yun
Wang, Liqing
Xiong, Xiaofang
Alaniz, Robert C.
de Figueiredo, Paul
Ren, Xingcong
Liu, Xiaoqi
Ryazonov, Alexey G.
Yang, Jin-Ming
Song, Jianxun
author_facet Das, Jugal Kishore
Ren, Yijie
Kumar, Anil
Peng, Hao-Yun
Wang, Liqing
Xiong, Xiaofang
Alaniz, Robert C.
de Figueiredo, Paul
Ren, Xingcong
Liu, Xiaoqi
Ryazonov, Alexey G.
Yang, Jin-Ming
Song, Jianxun
author_sort Das, Jugal Kishore
collection PubMed
description eEF-2K has important roles in stress responses and cellular metabolism. We report here a previously unappreciated but critical role of eEF-2K in regulating the fate and cytocidal activity of CD8(+) T cells. CD8(+) T cells from eEF-2K KO mice were more proliferative but had lower survival than their wild-type counterparts after their activation, followed by occurrence of premature senescence and exhaustion. eEF-2K KO CD8(+) T cells were more metabolically active and showed hyperactivation of the Akt-mTOR-S6K pathway. Loss of eEF-2K substantially impaired the activity of CD8(+) T cells. Furthermore, the antitumor efficacy and tumor infiltration of the CAR-CD8(+) T cells lacking eEF-2K were notably reduced as compared to the control CAR-CD8(+) T cells. Thus, eEF-2K is critically required for sustaining the viability and function of cytotoxic CD8(+) T cells, and therapeutic augmentation of this kinase may be exploited as a novel approach to reinforcing CAR-T therapy against cancer.
format Online
Article
Text
id pubmed-8809536
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher American Association for the Advancement of Science
record_format MEDLINE/PubMed
spelling pubmed-88095362022-02-16 Elongation factor-2 kinase is a critical determinant of the fate and antitumor immunity of CD8(+) T cells Das, Jugal Kishore Ren, Yijie Kumar, Anil Peng, Hao-Yun Wang, Liqing Xiong, Xiaofang Alaniz, Robert C. de Figueiredo, Paul Ren, Xingcong Liu, Xiaoqi Ryazonov, Alexey G. Yang, Jin-Ming Song, Jianxun Sci Adv Biomedicine and Life Sciences eEF-2K has important roles in stress responses and cellular metabolism. We report here a previously unappreciated but critical role of eEF-2K in regulating the fate and cytocidal activity of CD8(+) T cells. CD8(+) T cells from eEF-2K KO mice were more proliferative but had lower survival than their wild-type counterparts after their activation, followed by occurrence of premature senescence and exhaustion. eEF-2K KO CD8(+) T cells were more metabolically active and showed hyperactivation of the Akt-mTOR-S6K pathway. Loss of eEF-2K substantially impaired the activity of CD8(+) T cells. Furthermore, the antitumor efficacy and tumor infiltration of the CAR-CD8(+) T cells lacking eEF-2K were notably reduced as compared to the control CAR-CD8(+) T cells. Thus, eEF-2K is critically required for sustaining the viability and function of cytotoxic CD8(+) T cells, and therapeutic augmentation of this kinase may be exploited as a novel approach to reinforcing CAR-T therapy against cancer. American Association for the Advancement of Science 2022-02-02 /pmc/articles/PMC8809536/ /pubmed/35108044 http://dx.doi.org/10.1126/sciadv.abl9783 Text en Copyright © 2022 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY). https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Biomedicine and Life Sciences
Das, Jugal Kishore
Ren, Yijie
Kumar, Anil
Peng, Hao-Yun
Wang, Liqing
Xiong, Xiaofang
Alaniz, Robert C.
de Figueiredo, Paul
Ren, Xingcong
Liu, Xiaoqi
Ryazonov, Alexey G.
Yang, Jin-Ming
Song, Jianxun
Elongation factor-2 kinase is a critical determinant of the fate and antitumor immunity of CD8(+) T cells
title Elongation factor-2 kinase is a critical determinant of the fate and antitumor immunity of CD8(+) T cells
title_full Elongation factor-2 kinase is a critical determinant of the fate and antitumor immunity of CD8(+) T cells
title_fullStr Elongation factor-2 kinase is a critical determinant of the fate and antitumor immunity of CD8(+) T cells
title_full_unstemmed Elongation factor-2 kinase is a critical determinant of the fate and antitumor immunity of CD8(+) T cells
title_short Elongation factor-2 kinase is a critical determinant of the fate and antitumor immunity of CD8(+) T cells
title_sort elongation factor-2 kinase is a critical determinant of the fate and antitumor immunity of cd8(+) t cells
topic Biomedicine and Life Sciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8809536/
https://www.ncbi.nlm.nih.gov/pubmed/35108044
http://dx.doi.org/10.1126/sciadv.abl9783
work_keys_str_mv AT dasjugalkishore elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells
AT renyijie elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells
AT kumaranil elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells
AT penghaoyun elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells
AT wangliqing elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells
AT xiongxiaofang elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells
AT alanizrobertc elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells
AT defigueiredopaul elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells
AT renxingcong elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells
AT liuxiaoqi elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells
AT ryazonovalexeyg elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells
AT yangjinming elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells
AT songjianxun elongationfactor2kinaseisacriticaldeterminantofthefateandantitumorimmunityofcd8tcells